Abstract
Objective: To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). Background: Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. DESIGN/METHODS: Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs. Results: PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs. Conclusions: LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.
Original language | English (US) |
---|---|
Pages (from-to) | 201-209 |
Number of pages | 9 |
Journal | Parkinsonism and Related Disorders |
Volume | 62 |
DOIs | |
State | Published - May 2019 |
Keywords
- Adverse events
- Lumbar puncture
- Parkinson's disease
- Safety
ASJC Scopus subject areas
- Neurology
- Geriatrics and Gerontology
- Clinical Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Parkinsonism and Related Disorders, Vol. 62, 05.2019, p. 201-209.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Feasibility and safety of lumbar puncture in the Parkinson's disease research participants
T2 - Parkinson's Progression Marker Initiative (PPMI)
AU - The Parkinson's Progression Markers InitiativeSteering Committee
AU - Study Cores
AU - Site Investigators
AU - Coordinators
AU - Industry and Scientific Advisory Board
AU - Prakash, Neha
AU - Caspell-Garcia, Chelsea
AU - Coffey, Christopher
AU - Siderowf, Andrew
AU - Tanner, Caroline M.
AU - Kieburtz, Karl
AU - Mollenhauer, Brit
AU - Galasko, Douglas
AU - Merchant, Kalpana
AU - Foroud, Tatiana
AU - Chahine, Lana M.
AU - Weintraub, Daniel
AU - Casaceli, Cindy
AU - Dorsey, Ray
AU - Wilson, Renee
AU - Herzog, Margaret
AU - Daegele, Nichole
AU - Arnedo, Vanessa
AU - Frasier, Mark
AU - Sherer, Todd
AU - Marek, Ken
AU - Frank, Samuel
AU - Jennings, Danna
AU - Simuni, Tanya
AU - Marek, Kenneth
AU - Seibyl, John
AU - Tanner, Caroline
AU - Tosun-Turgut, Duygu
AU - Shaw, Leslie
AU - Trojanowski, John
AU - Singleton, Andrew
AU - Toga, Arthur
AU - Poewe, Werner
AU - Poston, Kathleen
AU - Chowdhury, Sohini
AU - Kopil, Catherine
AU - Casaceli, Cynthia
AU - Mahes, Sugi
AU - Salerno, Christina
AU - Crawford, Karen
AU - Casalin, Paola
AU - Malferrari, Giulia
AU - Weisz, Mali Gani
AU - Orr-Urtreger, Avi
AU - Montine, Thomas
AU - Russell, David
AU - Dahodwala, Nabila
AU - Giladi, Nir
AU - Factor, Stewart
AU - Hogarth, Penelope
N1 - Funding Information: Caroline M. Tanner serves on the Scientific Advisory Boards of the Michael J. Fox Foundation and the National Spasmodic Dysphonia Association as a voluntary consultant, and has provided paid consulting services to Pfizer Pharmaceuticals. She receives grant support from the Michael J. Fox Foundation , the Parkinson's Disease Foundation, the Department of Defense and the National Institutes of Health. Funding Information: Andrew Siderowf receives research grant support from the National Institute of Neurological Disorders and Stroke and the Michael J. Fox Foundation and serves as a consultant for Biogen, Denali, and Voyager Therapeutics. Funding Information: Christopher Coffey- Serves on the scientific advisory board for data safety and monitoring for NINDS and NIA, received a speaker honorarium for presenting a short course at Rho, Inc., is a consultant for ZZ Biotech, LLC, received research support from the Michael J. Fox Foundation , and is supported by NIH/NINDS , U01 NS077352 , PI, 10/01/11-09/30/18 (2) NIH/NINDS , U01 NS077108 , PI, 10/01/11-09/30/16 (3) NIH/NHLBI , U01 HL091843 , PI, 08/01/09-02/28/15 (4) NIH/NHLBI , U01 NS038529 , PI, 12/01/09-12/31/13 NIH/NINDS , (5) U01 NS079163 , 08/05/2012-07/31/2015 (6) NIH/NINDS , U01 NS082329 , 07/15/2013-06/30/2018 (7) NIH/NINDS , U01 NS084495 , 09/15/2013-07/31/2018 . Funding Information: Tanya Simuni has served as a consultant received consulting fees from Acadia, Abbvie, Allergan, Anavex, Avid, GE Medical, Eli Lilly and Company, Harbor, Ibsen, IMPAX, Lundbeck, Merz, Inc., the National Parkinson Foundation, Navidea, Pfizer, TEVA Pharmaceuticals, UCB Pharma, Voyager, US World Meds, and the Michael J. Fox Foundation for Parkinson's Research; Dr. Simuni has served as a speaker and received an honorarium from Acadia, IMPAX, Lundbeck, TEVA Pharmaceuticals, and UCB Pharma; Dr Simuni is on the Scientific advisory board for Anavex, Sanofi, MJFF. Dr. Simuni sits on the Advisory Board for IMPAX; Dr. Simuni has received research funding from the NINDS , MJFF , NPF , TEVA Pharmaceuticals , Auspex , Biotie , Civitas , Acorda , Lundbeck , Neuroderm , NINDS , National Institutes of Health , Northwestern Foundation , and the Michael J. Fox Foundation for Parkinson's Research; Dr. Simuni received funding support for educational programs from GE Medical , TEVA , and Lundbeck . Funding Information: PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Eli Lilly & Co., F. Hoffman-La Roche, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, MesoScale, Piramal, Pfizer, Prevail and UCB.Tanya Simuni has served as a consultant received consulting fees from Acadia, Abbvie, Allergan, Anavex, Avid, GE Medical, Eli Lilly and Company, Harbor, Ibsen, IMPAX, Lundbeck, Merz, Inc., the National Parkinson Foundation, Navidea, Pfizer, TEVA Pharmaceuticals, UCB Pharma, Voyager, US World Meds, and the Michael J. Fox Foundation for Parkinson's Research; Dr. Simuni has served as a speaker and received an honorarium from Acadia, IMPAX, Lundbeck, TEVA Pharmaceuticals, and UCB Pharma; Dr Simuni is on the Scientific advisory board for Anavex, Sanofi, MJFF. Dr. Simuni sits on the Advisory Board for IMPAX; Dr. Simuni has received research funding from the NINDS, MJFF, NPF, TEVA Pharmaceuticals, Auspex, Biotie, Civitas, Acorda, Lundbeck, Neuroderm, NINDS, National Institutes of Health, Northwestern Foundation, and the Michael J. Fox Foundation for Parkinson's Research; Dr. Simuni received funding support for educational programs from GE Medical, TEVA, and Lundbeck.Christopher Coffey- Serves on the scientific advisory board for data safety and monitoring for NINDS and NIA, received a speaker honorarium for presenting a short course at Rho, Inc., is a consultant for ZZ Biotech, LLC, received research support from the Michael J. Fox Foundation, and is supported by NIH/NINDS, U01 NS077352, PI, 10/01/11-09/30/18 (2) NIH/NINDS, U01 NS077108, PI, 10/01/11-09/30/16 (3) NIH/NHLBI, U01 HL091843, PI, 08/01/09-02/28/15(4) NIH/NHLBI, U01 NS038529, PI, 12/01/09-12/31/13 NIH/NINDS, (5) U01 NS079163, 08/05/2012-07/31/2015 (6) NIH/NINDS, U01 NS082329, 07/15/2013-06/30/2018 (7) NIH/NINDS, U01 NS084495, 09/15/2013-07/31/2018.Andrew Siderowf receives research grant support from the National Institute of Neurological Disorders and Stroke and the Michael J. Fox Foundation and serves as a consultant for Biogen, Denali, and Voyager Therapeutics.Caroline M. Tanner serves on the Scientific Advisory Boards of the Michael J. Fox Foundation and the National Spasmodic Dysphonia Association as a voluntary consultant, and has provided paid consulting services to Pfizer Pharmaceuticals. She receives grant support from the Michael J. Fox Foundation, the Parkinson's Disease Foundation, the Department of Defense and the National Institutes of Health.Karl Kieburtz serves as a consultant for the National Institutes of Health (NIH, NINDS), Acorda, Astellas Pharma, AstraZeneca, Auspex, Biotie, Britannia, Cangene, CHDI, Civitas, Clearpoint Strategy Group, Clintrex, Cynapsus, INC Research, IntecIsis, Lilly, Lundbeck, Medavante, Medivation, Melior Discovery, Neuroderm, Neurmedix, Omeros, Otsuka, Pfizer, Pharma2B, Prothena/Neotope/Elan Pharmaceutical, Raptor Pharmaceuticals, Roche/Genentech, Sage Bionetworks, Biotie, Stealth Peptides, Synagile, Teikoku Pharma, Titan, Turing Pharmaceuticals, Upsher-Smith, US WorldMeds, Vaccinex, Voyager, and Weston Brain Institute. Dr Kieburtz receives research grants from thr National Institutes of Health, Michael J. Fox Foundation, and Teva.Brit Mollenhauer is employed by Parcacelsus Kliniken Germany and the University Medical Center Goettingen; BM has received independent research grants from TEVA-Pharma, Desitin, Boehringer Ingelheim, GE Healthcare and honoraria for consultancy from Bayer Schering Pharma AG, Roche, AbbVie, TEVA-Pharma, Biogen, UCB and for presentations from GlaxoSmithKline, Orion Pharma, TEVA-Pharma and travel costs from TEVA-Pharma. BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson's Research and has received grants from the BMBF, EU, Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson's Research, Stifterverband für die deutsche Wissenschaft, and has scientific collaborations with Roche, Bristol Myers Squibb, Ely Lilly, Covance and Biogen.Douglas Galasko receives research funding from National Institutes of Health, Michael J. Fox Foundation, and Eli Lilly and Esai. He is a paid Editor for Alzheimer's Research and Therapy. He is a consultant for vTv Therapeutics and serves on a DSMB for Prothena.Tatiana Foroud has received funding from The Michael J. Fox Foundation, the NIH, San Diego State University, The University of Texas at Austin, and Waggoner Center for Alcohol and Addiction Research.Lana M. Chahine receives research support from the Michael J. Fox Foundation, has received travel payment from MJFF to MJFF conferences, is a paid consultant to MJFF, receives research support for a clinical trial sponsored by Voyager Therapeutics, received travel payments from Voyager Therapeutics to Investigator meeting, and receives royalties from Wolters Kluwel (for book authorship).Daniel Weintraub has received research funding or support from Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health, Novartis Pharmaceuticals, Department of Veterans Affairs, Avid Radiopharmaceuticals, Alzheimer's Disease Cooperative Study, and the International Parkinson and Movement Disorder Society; honoraria for consultancy from Acadia, Biogen, Biotie (Acorda), Bracket, Clintrex LLC, Eisai Inc., Eli Lilly, Lundbeck, Roche, Takeda, UCB, and the CHDI Foundation; license fee payments from the University of Pennsylvania for the Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease (QUIP) and Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease ‐ Rating Scale (QUIP‐RS); royalties from Wolters Kluweland; and fees for legal consultation for lawsuits related to medication prescribing in patients with Parkinson's disease.Kenneth Marek is a consultant for Pfizer, GE Healthcare, Merck, Lilly, BMS, Piramal, Prothena, Neurophage, nLife, Roche, and receives funding for the following grants: W81XWH-06-1-0678 Establishing an ‘at risk’ cohort for Parkinson Disease Neuroprevention using olfactory testing and DAT imaging, DOD, Investigator 10/1/06–09/30/15; Parkinson Progression Marker Initiative (PPMI), Michael J. Fox Foundation, Principal Investigator 6/15/09–6/14/18; DAT imaging in LRRK2 family members, the Michael J. Fox Foundation, Principal Investigator 1/15/10–1/14/15. Ownership in Molecular NeuroImaging, LL. Funding Information: Tatiana Foroud has received funding from The Michael J. Fox Foundation , the NIH , San Diego State University , The University of Texas at Austin , and Waggoner Center for Alcohol and Addiction Research . Funding Information: Douglas Galasko receives research funding from National Institutes of Health , Michael J. Fox Foundation , and Eli Lilly and Esai . He is a paid Editor for Alzheimer's Research and Therapy. He is a consultant for vTv Therapeutics and serves on a DSMB for Prothena. Funding Information: PPMI ? a public-private partnership ? is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen Idec, Bristol-Myers Squibb, Covance, Eli Lilly & Co., F. Hoffman-La Roche, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, MesoScale, Piramal, Pfizer, Prevail and UCB.Tanya Simuni has served as a consultant received consulting fees from Acadia, Abbvie, Allergan, Anavex, Avid, GE Medical, Eli Lilly and Company, Harbor, Ibsen, IMPAX, Lundbeck, Merz, Inc., the National Parkinson Foundation, Navidea, Pfizer, TEVA Pharmaceuticals, UCB Pharma, Voyager, US World Meds, and the Michael J. Fox Foundation for Parkinson's Research; Dr. Simuni has served as a speaker and received an honorarium from Acadia, IMPAX, Lundbeck, TEVA Pharmaceuticals, and UCB Pharma; Dr Simuni is on the Scientific advisory board for Anavex, Sanofi, MJFF. Dr. Simuni sits on the Advisory Board for IMPAX; Dr. Simuni has received research funding from the NINDS, MJFF, NPF, TEVA Pharmaceuticals, Auspex, Biotie, Civitas, Acorda, Lundbeck, Neuroderm, NINDS, National Institutes of Health, Northwestern Foundation, and the Michael J. Fox Foundation for Parkinson's Research; Dr. Simuni received funding support for educational programs from GE Medical, TEVA, and Lundbeck.Christopher Coffey- Serves on the scientific advisory board for data safety and monitoring for NINDS and NIA, received a speaker honorarium for presenting a short course at Rho, Inc., is a consultant for ZZ Biotech, LLC, received research support from the Michael J. Fox Foundation, and is supported by NIH/NINDS, U01 NS077352, PI, 10/01/11-09/30/18 (2) NIH/NINDS, U01 NS077108, PI, 10/01/11-09/30/16 (3) NIH/NHLBI, U01 HL091843, PI, 08/01/09-02/28/15(4) NIH/NHLBI, U01 NS038529, PI, 12/01/09-12/31/13 NIH/NINDS, (5) U01 NS079163, 08/05/2012-07/31/2015 (6) NIH/NINDS, U01 NS082329, 07/15/2013-06/30/2018 (7) NIH/NINDS, U01 NS084495, 09/15/2013-07/31/2018.Andrew Siderowf receives research grant support from the National Institute of Neurological Disorders and Stroke and the Michael J. Fox Foundation and serves as a consultant for Biogen, Denali, and Voyager Therapeutics.Caroline M. Tanner serves on the Scientific Advisory Boards of the Michael J. Fox Foundation and the National Spasmodic Dysphonia Association as a voluntary consultant, and has provided paid consulting services to Pfizer Pharmaceuticals. She receives grant support from the Michael J. Fox Foundation, the Parkinson's Disease Foundation, the Department of Defense and the National Institutes of Health.Karl Kieburtz serves as a consultant for the National Institutes of Health (NIH, NINDS), Acorda, Astellas Pharma, AstraZeneca, Auspex, Biotie, Britannia, Cangene, CHDI, Civitas, Clearpoint Strategy Group, Clintrex, Cynapsus, INC Research, IntecIsis, Lilly, Lundbeck, Medavante, Medivation, Melior Discovery, Neuroderm, Neurmedix, Omeros, Otsuka, Pfizer, Pharma2B, Prothena/Neotope/Elan Pharmaceutical, Raptor Pharmaceuticals, Roche/Genentech, Sage Bionetworks, Biotie, Stealth Peptides, Synagile, Teikoku Pharma, Titan, Turing Pharmaceuticals, Upsher-Smith, US WorldMeds, Vaccinex, Voyager, and Weston Brain Institute. Dr Kieburtz receives research grants from thr National Institutes of Health, Michael J. Fox Foundation, and Teva.Brit Mollenhauer is employed by Parcacelsus Kliniken Germany and the University Medical Center Goettingen; BM has received independent research grants from TEVA-Pharma, Desitin, Boehringer Ingelheim, GE Healthcare and honoraria for consultancy from Bayer Schering Pharma AG, Roche, AbbVie, TEVA-Pharma, Biogen, UCB and for presentations from GlaxoSmithKline, Orion Pharma, TEVA-Pharma and travel costs from TEVA-Pharma. BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson's Research and has received grants from the BMBF, EU, Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson's Research, Stifterverband f?r die deutsche Wissenschaft, and has scientific collaborations with Roche, Bristol Myers Squibb, Ely Lilly, Covance and Biogen.Douglas Galasko receives research funding from National Institutes of Health, Michael J. Fox Foundation, and Eli Lilly and Esai. He is a paid Editor for Alzheimer's Research and Therapy. He is a consultant for vTv Therapeutics and serves on a DSMB for Prothena.Tatiana Foroud has received funding from The Michael J. Fox Foundation, the NIH, San Diego State University, The University of Texas at Austin, and Waggoner Center for Alcohol and Addiction Research.Lana M. Chahine receives research support from the Michael J. Fox Foundation, has received travel payment from MJFF to MJFF conferences, is a paid consultant to MJFF, receives research support for a clinical trial sponsored by Voyager Therapeutics, received travel payments from Voyager Therapeutics to Investigator meeting, and receives royalties from Wolters Kluwel (for book authorship).Daniel Weintraub has received research funding or support from Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health, Novartis Pharmaceuticals, Department of Veterans Affairs, Avid Radiopharmaceuticals, Alzheimer's Disease Cooperative Study, and the International Parkinson and Movement Disorder Society; honoraria for consultancy from Acadia, Biogen, Biotie (Acorda), Bracket, Clintrex LLC, Eisai Inc., Eli Lilly, Lundbeck, Roche, Takeda, UCB, and the CHDI Foundation; license fee payments from the University of Pennsylvania for the Questionnaire for Impulsive?Compulsive Disorders in Parkinson's Disease (QUIP) and Questionnaire for Impulsive?Compulsive Disorders in Parkinson's Disease ? Rating Scale (QUIP?RS); royalties from Wolters Kluweland; and fees for legal consultation for lawsuits related to medication prescribing in patients with Parkinson's disease.Kenneth Marek is a consultant for Pfizer, GE Healthcare, Merck, Lilly, BMS, Piramal, Prothena, Neurophage, nLife, Roche, and receives funding for the following grants: W81XWH-06-1-0678 Establishing an 'at risk' cohort for Parkinson Disease Neuroprevention using olfactory testing and DAT imaging, DOD, Investigator 10/1/06?09/30/15; Parkinson Progression Marker Initiative (PPMI), Michael J. Fox Foundation, Principal Investigator 6/15/09?6/14/18; DAT imaging in LRRK2 family members, the Michael J. Fox Foundation, Principal Investigator 1/15/10?1/14/15. Ownership in Molecular NeuroImaging, LL. Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. Publisher Copyright: © 2019 Elsevier Ltd
PY - 2019/5
Y1 - 2019/5
N2 - Objective: To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). Background: Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. DESIGN/METHODS: Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs. Results: PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs. Conclusions: LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.
AB - Objective: To determine the feasibility, safety and tolerability of lumbar punctures (LPs) in research participants with early Parkinson disease (PD), subjects without evidence of dopaminergic deficiency (SWEDDs) and healthy volunteers (HC). Background: Cerebrospinal fluid (CSF) analysis is becoming an essential part of the biomarkers discovery effort in PD with still limited data on safety and feasibility of serial LPs in PD participants. DESIGN/METHODS: Parkinson's Progression Marker Initiative (PPMI) is a longitudinal observation study designed to identify PD progression biomarkers. All PPMI participants undergo LP at baseline, 6, 12 months and yearly thereafter. CSF collection is performed by a trained investigator using predominantly atraumatic needles. Adverse events (AEs) are monitored by phone one week after LP completion. We analyzed safety data from baseline LPs. Results: PPMI enrolled 683 participants (423 PD/196 HC/64 SWEDDs) from 23 study sites. CSF was collected at baseline in 97.5% of participants, of whom 5.4% underwent collection under fluoroscopy. 23% participants reported any related AEs, 68% of all AE were mild while 5.6% were severe. The most common AEs were headaches (13%) and low back pain (6.5%) and both occurred more commonly in HC and SWEDDs compared to PD participants. Factors associated with higher incidence of AEs across the cohorts included female gender, younger age and use of traumatic needles with larger diameter. AEs largely did not impact compliance with the future LPs. Conclusions: LPs are safe and feasible in PD research participants. Specific LP techniques (needle type and gauge) may reduce the overall incidence of AEs.
KW - Adverse events
KW - Lumbar puncture
KW - Parkinson's disease
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=85061045418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061045418&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2018.12.025
DO - 10.1016/j.parkreldis.2018.12.025
M3 - Article
C2 - 30738748
AN - SCOPUS:85061045418
SN - 1353-8020
VL - 62
SP - 201
EP - 209
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -